CellBead Neuro
We have developed a Drug-Eluting Bead for the treatment of neurological trauma and neurological degeneration. The bead releases a proprietary Glucagon Like Peptide (GLP-1), whose activity against programmed cell death has been established in pre-clinical work at the International Neuroscience Institute (INI) in Hannover. A clinical trial protocol has been developed with INI and the regulatory authorities have approved a Phase I/II trial for the treatment of Intra-Cerebral Haemorrhage (ICH), a severe form of stroke. Every year 125 000 people in the US and the five leading European countries suffer an ICH and treatment options are limited.
Despite the number of people affected, CellMed’s stroke programme has very limited competition. In recent years, the most valuable developments have been improved patient management protocols, rather than new therapeutic agents whose progress has been consistently disappointing. CellMed aims to be the first company to treat a stroke patient with a stem cell product. At least two other companies have stem cell programmes for stroke and at least seven other companies have announced that they are close to the start of a clinical trial for a stem cell product in indications that include stroke, diabetes and cancer. The scientific and regulatory challenge to this type of technology remains considerable for all companies.
On 2nd December 2008, the INI announced the recruitment of the first patient in the Stroke trial in the press release that follows below; and also issued a video that was made with the cooperation of the patient who received the treatment.
- 'First ever Treatment of Stroke Patient with Stem Cell Therapy Product', 2 December 2008
- Video of the first patient enrolled
